TW202233685A - 用於治療靶向tl1a之發炎疾病之方法、系統及套組 - Google Patents

用於治療靶向tl1a之發炎疾病之方法、系統及套組

Info

Publication number
TW202233685A
TW202233685A TW110142315A TW110142315A TW202233685A TW 202233685 A TW202233685 A TW 202233685A TW 110142315 A TW110142315 A TW 110142315A TW 110142315 A TW110142315 A TW 110142315A TW 202233685 A TW202233685 A TW 202233685A
Authority
TW
Taiwan
Prior art keywords
seq
polymorphisms
tl1a
amino acid
antibody
Prior art date
Application number
TW110142315A
Other languages
English (en)
Chinese (zh)
Inventor
勞倫斯 克魯伊登尼爾
馬修 雷斯曼
馬雅 薩布里波爾
派翠西雅 麥克尼利
傑夫瑞 Ｄ 華德金斯
珍妮娜 比爾斯柏洛夫
辛蒂 Ｔ 迪克森
達默特 Ｐ 麥戈文
拉法爾 羅賈斯
李達霖
Original Assignee
美商普羅米修斯生物科學股份有限公司
美國錫安山醫學中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普羅米修斯生物科學股份有限公司, 美國錫安山醫學中心 filed Critical 美商普羅米修斯生物科學股份有限公司
Publication of TW202233685A publication Critical patent/TW202233685A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110142315A 2020-11-13 2021-11-12 用於治療靶向tl1a之發炎疾病之方法、系統及套組 TW202233685A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063113657P 2020-11-13 2020-11-13
US63/113,657 2020-11-13
US202163136153P 2021-01-11 2021-01-11
US63/136,153 2021-01-11
US202163147165P 2021-02-08 2021-02-08
US63/147,165 2021-02-08
US202163181074P 2021-04-28 2021-04-28
US63/181,074 2021-04-28
US202163226032P 2021-07-27 2021-07-27
US63/226,032 2021-07-27

Publications (1)

Publication Number Publication Date
TW202233685A true TW202233685A (zh) 2022-09-01

Family

ID=81602611

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142315A TW202233685A (zh) 2020-11-13 2021-11-12 用於治療靶向tl1a之發炎疾病之方法、系統及套組

Country Status (14)

Country Link
US (1) US20230272098A1 (https=)
EP (1) EP4244251A4 (https=)
JP (1) JP2023551602A (https=)
KR (1) KR20230140553A (https=)
AU (1) AU2021377688A1 (https=)
BR (1) BR112023009172A2 (https=)
CA (1) CA3197828A1 (https=)
CL (1) CL2024001693A1 (https=)
CO (1) CO2023007607A2 (https=)
IL (1) IL302791A (https=)
MX (1) MX2023005688A (https=)
PH (1) PH12023500011A1 (https=)
TW (1) TW202233685A (https=)
WO (1) WO2022103961A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
WO2022232253A1 (en) * 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
US20260066079A1 (en) * 2022-11-23 2026-03-05 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4646434A2 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
EP4646443A1 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
KR20260013470A (ko) * 2023-05-17 2026-01-28 제넨테크, 인크. 항-tl1a 항체 치료 방법
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004928D0 (sv) * 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
WO2014186750A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10626180B2 (en) * 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP7332627B2 (ja) * 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
ES2962715T3 (es) * 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
JP2022533956A (ja) * 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス

Also Published As

Publication number Publication date
CL2024001693A1 (es) 2024-11-29
US20230272098A1 (en) 2023-08-31
KR20230140553A (ko) 2023-10-06
EP4244251A4 (en) 2025-04-16
AU2021377688A1 (en) 2023-06-29
AU2021377688A9 (en) 2024-09-12
JP2023551602A (ja) 2023-12-08
BR112023009172A2 (pt) 2023-10-03
PH12023500011A1 (en) 2024-03-11
WO2022103961A1 (en) 2022-05-19
EP4244251A1 (en) 2023-09-20
CA3197828A1 (en) 2022-05-19
IL302791A (en) 2023-07-01
MX2023005688A (es) 2023-07-18
CO2023007607A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
US20230272098A1 (en) Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
TWI832808B (zh) 中和抗tl1a之單株抗體
US11292848B2 (en) Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
US20260066079A1 (en) Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
TWI713436B (zh) 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
US20220290241A1 (en) Predicting extraintestinal manifestations of inflammatory bowel disease
TWI871367B (zh) 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
US20240209103A1 (en) Patient selection methods and kits for therapies targeting tl1a
KR20210005169A (ko) 최적화된 항tl1a 항체
EP3904382A1 (en) Anti-il-23p19 antibody and uses thereof
TW201809011A (zh) 結合蛋白質及其使用方法
CN104244979A (zh) 使用il-17拮抗剂治疗强直性脊柱炎的方法
CN112533632A (zh) 用于预防和治疗癌症的gremlin-1拮抗剂
KR20170093182A (ko) 인간 c-maf에 대한 결합 구성원
JP7672532B2 (ja) アイソフォーム選択的抗ｔｇｆ－ベータ抗体及び使用方法
WO2015157634A1 (en) Anti-erbb antibodies and methods of use thereof
CN117279943A (zh) 通过靶向tl1a来治疗炎性疾病的方法、系统和试剂盒
CN115698719A (zh) 用于癌症免疫疗法的方法和组合物
AU2024280413A9 (en) Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a
EA048906B1 (ru) Гуманизированные антитела к tnf-подобному лиганду 1a (tl1a) и варианты их применения